TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 34794789

Group type: EXPERIMENTAL
Intervention: SÜPEVAC unit
Number of subjects: 22

Group type: COMPARATOR
Intervention: Wall suction
Number of subjects: 22
Study: 34431174

Group type: EXPERIMENTAL
Intervention: Intervention twice per week (20-30 min sessions for 10 weeks, 1000 trials; 400-600 min total)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Intervention once per week (20-30 min sessions for 10 weeks, 500 trials; 200-300 min total)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: All past tense allomorphs treated with the intervention
Number of subjects: 29
Study: 32391709

Group type: EXPERIMENTAL
Intervention: Shamiri-Digital intervention
Number of subjects: 103

Group type: COMPARATOR
Intervention: Study-skills control intervention
Number of subjects: 103
Study: 35590144

Group type: EXPERIMENTAL
Intervention: Helping Hand (HH)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: GloReha (GR)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: GRHH (50% GR and 50% HH)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional Treatment (CT)
Number of subjects: 60
Study: 34098818

Group type: EXPERIMENTAL
Intervention: Pelvic Floor Muscle Exercise + Kinesio Taping (PFME + KT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pelvic Floor Muscle Exercise + External Electrical Stimulation (PFME + ES)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pelvic Floor Muscle Exercise (PFME)
Number of subjects: 0
Study: 37597578

Group type: EXPERIMENTAL
Intervention: Neratinib + fulvestrant + trastuzumab (N + F + T)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Fulvestrant alone
Number of subjects: 71

Group type: COMPARATOR
Intervention: Fulvestrant + trastuzumab (F + T)
Number of subjects: 71
Study: 34600130

Group type: EXPERIMENTAL
Intervention: ANICGM (non-invasive continuous glucose monitor)
Number of subjects: 15
Study: 33395981

Group type: EXPERIMENTAL
Intervention: Alpha-rhythm EEG neurofeedback (NFB)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Sham-control
Number of subjects: 36
Study: 35680447

Group type: EXPERIMENTAL
Intervention: Fusion imaging group (preoperative CTA and image fusion reconstruction)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Control group (no preoperative CTA and image fusion reconstruction)
Number of subjects: 56
Study: 33628717

Group type: EXPERIMENTAL
Intervention: Propolis (75 mg three times a day)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study: 35386013

Group type: EXPERIMENTAL
Intervention: FMXIN001 (intranasal powder-based naloxone formulation)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Narcan® (nasal liquid spray)
Number of subjects: 56
Study: 33780806

Group type: EXPERIMENTAL
Intervention: Logotherapy (LT)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy (ACT)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group (basic information workshop)
Number of subjects: 48
Study: 35581545

Group type: EXPERIMENTAL
Intervention: fremanezumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 0
Study: 34498370

Group type: EXPERIMENTAL
Intervention: Quality Improvement (QI) intervention
Number of subjects: 13447

Group type: COMPARATOR
Intervention: Standard of Care (SOC)
Number of subjects: 13447
Study: 33615766

Group type: EXPERIMENTAL
Intervention: Mirror cross education
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Kinetic chain approach
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 39
Study: 34836120

Group type: EXPERIMENTAL
Intervention: Dry Immersion (DI) for 5 days
Number of subjects: 14
Study: 33742262

Group type: EXPERIMENTAL
Intervention: Zinc toothpaste (test)
Number of subjects: 212

Group type: COMPARATOR
Intervention: Fluoride dentifrice (control)
Number of subjects: 212
Study: 32035739

Group type: EXPERIMENTAL
Intervention: Home talks (HTs) delivered by village health workers (VHWs)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control topics (randomly assigned)
Number of subjects: 0
Study: 34231265

Group type: EXPERIMENTAL
Intervention: Jiangnan Dietary pattern
Number of subjects: 502

Group type: COMPARATOR
Intervention: Not specified
Number of subjects: 502
Study: 32472417

Group type: EXPERIMENTAL
Intervention: Oncotype DX recurrence score (RS) testing
Number of subjects: 3068

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy for MBC patients with low RS
Number of subjects: 3068

Group type: COMPARATOR
Intervention: Adjuvant chemotherapy for FBC patients with low RS
Number of subjects: 3068

Group type: EXPERIMENTAL
Intervention: Overall chemotherapy rates
Number of subjects: 3068
Study: 86266805

Group type: EXPERIMENTAL
Intervention: R3: rifampin plus streptomycin plus isoniazid plus pyrazinamide daily for 3 months
Number of subjects: 694

Group type: EXPERIMENTAL
Intervention: R5: rifampin plus streptomycin plus isoniazid plus pyrazinamide daily for 3 months followed by streptomycin plus isoniazid plus pyrazinamide twice weekly for 2 months
Number of subjects: 694

Group type: EXPERIMENTAL
Intervention: Z5: streptomycin plus isoniazid plus pyrazinamide twice weekly for 2 months without rifampin
Number of subjects: 694

Group type: EXPERIMENTAL
Intervention: R3 and R5 series combined
Number of subjects: 694

Group type: EXPERIMENTAL
Intervention: Z5
Number of subjects: 694
Study: 33903977

Group type: EXPERIMENTAL
Intervention: Olweus Bullying Prevention Program (OBPP)
Number of subjects: 2755
Study: 34051342

Group type: EXPERIMENTAL
Intervention: Beetroot juice (BRJ) - 70 ml dose per day for 20 days (12.5 mmol nitrate per day; n = 11)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Non-nitrate calorie matched control (n = 11)
Number of subjects: 22
Study: 33291988

Group type: EXPERIMENTAL
Intervention: Music (fast-tempo, 140 bpm)
Number of subjects: 14

Group type: COMPARATOR
Intervention: No music
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Music
Number of subjects: 14
Study: 34043853

Group type: EXPERIMENTAL
Intervention: TD‐GCBT + TAU
Number of subjects: 1061

Group type: COMPARATOR
Intervention: TAU alone
Number of subjects: 1061
Study: 33104675

Group type: EXPERIMENTAL
Intervention: Asymmetric learning framework for ghost imaging (GI)
Number of subjects: 0

Group type: COMPARATOR
Intervention: GIDL with a symmetric loss function
Number of subjects: 0
Study: 36105074

Group type: EXPERIMENTAL
Intervention: Motivational enhanced adherence counseling and point-of-care viral load monitoring
Number of subjects: 50

Group type: COMPARATOR
Intervention: Routine care (laboratory-based VL monitoring and standard EAC)
Number of subjects: 50
Study: 33113253

Group type: EXPERIMENTAL
Intervention: E&S (30-second sprints during prolonged low-intensity cycling)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: E&S
Number of subjects: 12

Group type: COMPARATOR
Intervention: E&S and E
Number of subjects: 12
Study: 32854537

Group type: EXPERIMENTAL
Intervention: High-protein/moderate-carbohydrate (HP/MCHO) meal
Number of subjects: 14

Group type: COMPARATOR
Intervention: Low-protein/high-carbohydrate (LP/HCHO) meal
Number of subjects: 14
Study: 35800026

Group type: EXPERIMENTAL
Intervention: 4-week online High-Intensity Interval Training (HIIT) program, 3 sessions per week
Number of subjects: 30

Group type: COMPARATOR
Intervention: No-intervention control group
Number of subjects: 30
Study: 32162174

Group type: EXPERIMENTAL
Intervention: Healthy Families New York (HFNY)
Number of subjects: 942

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 942
Study: 36461695

Group type: EXPERIMENTAL
Intervention: Pre-urodynamic single-dose Levofloxacin (500 mg administered one hour before the urodynamic study)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Post-urodynamic Levofloxacin (500 mg once daily for three days following the urodynamic study)
Number of subjects: 126
Study: 33325641

Group type: EXPERIMENTAL
Intervention: SNFtool and DIABLO integration in study 1
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: SNF integration in studies 2 and 3
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: DIABLO in studies 2 and 3
Number of subjects: 59
Study: 32410398

Group type: EXPERIMENTAL
Intervention: Cervical mucus removal prior to intrauterine insemination
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 33599247

Group type: EXPERIMENTAL
Intervention: Ivermectin 6 mg regime
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Ivermectin 12 mg regime (given Q84 h for 2 weeks)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Control (Lopinavir/Ritonavir)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Ivermectin (both doses)
Number of subjects: 62
Study: 34857843

Group type: EXPERIMENTAL
Intervention: Navigation-guided balloon Eustachian tuboplasty (BET)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Medical management (MM)
Number of subjects: 31
Study: 36173481

Group type: EXPERIMENTAL
Intervention: High Na+ (60 mmol L-1 sodium)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Low Na+ (21 mmol L-1 sodium)
Number of subjects: 11
Study: 33694346

Group type: EXPERIMENTAL
Intervention: Occipitoatlantal decompression (OA-D) for 5 minutes followed by 10 minutes of rest
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Transcutaneous auricular vagus nerve stimulation (taVNS) for 15 minutes
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group (CTR) with 15 minutes of rest
Number of subjects: 28
Study: 35101711

Group type: EXPERIMENTAL
Intervention: Tailored physiotherapy delivered over 6 months, including pelvic floor muscle training in clinic and at home.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Smartphone app to aid motivation and monitoring.
Number of subjects: 0
Study: 34050798

Group type: EXPERIMENTAL
Intervention: Ultrasound group
Number of subjects: 80

Group type: COMPARATOR
Intervention: Palpation group
Number of subjects: 80
Study: 35679281

Group type: EXPERIMENTAL
Intervention: SWIS (School Based Social Work)
Number of subjects: 280

Group type: COMPARATOR
Intervention: Comparison arm (schools without social workers)
Number of subjects: 280
Study: 32398852

Group type: EXPERIMENTAL
Intervention: Simultaneous double-protocol therapy (intravitreal dexamethasone implant and ranibizumab)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Ranibizumab monotherapy
Number of subjects: 46
Study: 32512517

Group type: EXPERIMENTAL
Intervention: HIV-1 DNA ≥3 log10 copies/million PBMC
Number of subjects: 2019

Group type: EXPERIMENTAL
Intervention: HIV-1 RNA ≥5 log10 copies/ml
Number of subjects: 2019

Group type: EXPERIMENTAL
Intervention: HIV-1 DNA levels ≥3 log10 copies/million PBMC (multivariate analysis)
Number of subjects: 2019

Group type: EXPERIMENTAL
Intervention: Baseline plasma HIV-1 RNA
Number of subjects: 2019
Study: 35768119

Group type: EXPERIMENTAL
Intervention: Preoperative carbohydrate-loading drinks (4×200 mL evening before surgery and 2×200 mL the morning of surgery) and early postoperative nutritional protein supplement drinks two times per day for 14 days
Number of subjects: 64

Group type: COMPARATOR
Intervention: Control group receiving an equivalent volume of water
Number of subjects: 64
Study: 34476742

Group type: EXPERIMENTAL
Intervention: Flipped text resource
Number of subjects: 281

Group type: EXPERIMENTAL
Intervention: Flipped video resource
Number of subjects: 281

Group type: COMPARATOR
Intervention: Traditional lecture (control)
Number of subjects: 281
Study: 32584754

Group type: EXPERIMENTAL
Intervention: Advertisement cue (taking control of one's future)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Advertisement cue combination (financial security and taking control of one's future)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Motivation to enroll
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cue processing
Number of subjects: 0
Study: 33019807

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided paravertebral block
Number of subjects: 40

Group type: COMPARATOR
Intervention: Thoracoscopic-guided paravertebral block
Number of subjects: 40
Study: 33086160

Group type: EXPERIMENTAL
Intervention: Mixed amphetamine salts-extended-release (MAS-ER), titrated up to 80 mg daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 35247334

Group type: EXPERIMENTAL
Intervention: Topical LHA510 administered twice a day for 8 weeks and then 3 times a day for the last 4 weeks
Number of subjects: 90

Group type: COMPARATOR
Intervention: Vehicle (placebo) administered twice a day for 8 weeks and then 3 times a day for the last 4 weeks
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Topical LHA510
Number of subjects: 90
Study: 33994064

Group type: EXPERIMENTAL
Intervention: Overnight fast (0100 h–0600 h)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Usual dietary habits (control period)
Number of subjects: 19
Study: 32164673

Group type: EXPERIMENTAL
Intervention: Antimicrobial therapy (trimethoprim 160 mg/sulfamethoxazole 800 mg twice a day plus folic acid 5 mg daily or doxycycline 100 mg once daily if body weight is < 50 kg or 100 mg twice daily if ≥50 kg)
Number of subjects: 500

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 500
Study: 82110185

Group type: EXPERIMENTAL
Intervention: Carbamazepine
Number of subjects: 68

Group type: COMPARATOR
Intervention: Clomethiazole
Number of subjects: 68
Study: 35482217

Group type: EXPERIMENTAL
Intervention: Eccentric elbow flexor exercise (EE)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Concentric exercise (CE)
Number of subjects: 11
Study: 32331734

Group type: EXPERIMENTAL
Intervention: Physical exercise
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (no physical exercise)
Number of subjects: 50
Study: 34982157

Group type: EXPERIMENTAL
Intervention: Biweekly saliva testing
Number of subjects: 592

Group type: COMPARATOR
Intervention: Biweekly midturbinate swabbing
Number of subjects: 592

Group type: COMPARATOR
Intervention: Weekly midturbinate swabbing
Number of subjects: 592
Study: 33387236

Group type: EXPERIMENTAL
Intervention: Naturalistic behavioral social skills intervention (SIMI)
Number of subjects: 0
Study: 33417481

Group type: EXPERIMENTAL
Intervention: Early interdisciplinary supportive care (ESC) integrated into standard oncologic care
Number of subjects: 328

Group type: COMPARATOR
Intervention: Standard care (SC)
Number of subjects: 328
Study: 33184828

Group type: EXPERIMENTAL
Intervention: Planned Cesarean Delivery (PCD)
Number of subjects: 343

Group type: COMPARATOR
Intervention: Vaginal Delivery (PVD)
Number of subjects: 343
Study: 34698931

Group type: EXPERIMENTAL
Intervention: 1 g TXA i.v. preoperatively
Number of subjects: 52

Group type: COMPARATOR
Intervention: No TXA
Number of subjects: 52
Study: 32880572

Group type: EXPERIMENTAL
Intervention: 6 months' trastuzumab
Number of subjects: 4088

Group type: COMPARATOR
Intervention: 12 months' trastuzumab
Number of subjects: 4088
Study: 36056882

Group type: EXPERIMENTAL
Intervention: FIRM-guided ablation
Number of subjects: 269

Group type: COMPARATOR
Intervention: Conventional ablation
Number of subjects: 269
Study: 34133089

Group type: EXPERIMENTAL
Intervention: Vortioxetine (5 mg)
Number of subjects: 7269

Group type: EXPERIMENTAL
Intervention: Vortioxetine (10 mg)
Number of subjects: 7269

Group type: EXPERIMENTAL
Intervention: Vortioxetine (15 mg)
Number of subjects: 7269

Group type: EXPERIMENTAL
Intervention: Vortioxetine (20 mg)
Number of subjects: 7269

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7269
Study: 32962749

Group type: EXPERIMENTAL
Intervention: Tai Chi/Qigong (TCQ) intervention
Number of subjects: 72

Group type: COMPARATOR
Intervention: Sham qigong control
Number of subjects: 72

Group type: COMPARATOR
Intervention: Standard of care control
Number of subjects: 72
Study: 35792053

Group type: EXPERIMENTAL
Intervention: Approach Bias Modification (ApBM)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Control (sham training)
Number of subjects: 300
Study: 32936480

Group type: EXPERIMENTAL
Intervention: Tisseel plus PEP (TEPEP) patch
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Tisseel patch alone
Number of subjects: 3

Group type: COMPARATOR
Intervention: Control (FDP tendon repair alone)
Number of subjects: 3
Study: 32211049

Group type: COMPARATOR
Intervention: Food-secure households
Number of subjects: 525

Group type: EXPERIMENTAL
Intervention: Moderately food-insecure households
Number of subjects: 525

Group type: EXPERIMENTAL
Intervention: Food-insecure households
Number of subjects: 525

Group type: EXPERIMENTAL
Intervention: Overall child undernutrition
Number of subjects: 525

Group type: EXPERIMENTAL
Intervention: Household food insecurity
Number of subjects: 525
Study: 35083238

Group type: EXPERIMENTAL
Intervention: Faecal microbiota transplantation (FMT)
Number of subjects: 60
Study: 35879196

Group type: EXPERIMENTAL
Intervention: 5000 IU HCG
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: 6500 IU HCG
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: 10,000 IU HCG
Number of subjects: 94

Group type: COMPARATOR
Intervention: 6500 IU HCG with vaginal progesterone
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Comparison between groups
Number of subjects: 94
Study: 34499672

Group type: EXPERIMENTAL
Intervention: Metformin (2000 mg/day)
Number of subjects: 117

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: PCOS status (mothers)
Number of subjects: 117

Group type: COMPARATOR
Intervention: Reference population
Number of subjects: 117
Study: 36045119

Group type: EXPERIMENTAL
Intervention: 30 mg oral hydrocortisone
Number of subjects: 120

Group type: COMPARATOR
Intervention: Matched placebo
Number of subjects: 120
Study: 33713817

Group type: EXPERIMENTAL
Intervention: PEG IFN‐α2b plus SOC
Number of subjects: 40

Group type: COMPARATOR
Intervention: SOC
Number of subjects: 40
Study: 35150597

Group type: EXPERIMENTAL
Intervention: Bismuth-containing quadruple therapy (BQT)
Number of subjects: 292

Group type: EXPERIMENTAL
Intervention: Rabeprazole plus amoxicillin dual therapy (RADT)
Number of subjects: 292

Group type: EXPERIMENTAL
Intervention: Furazolidone (RFDT)
Number of subjects: 292
Study: 33283636

Group type: EXPERIMENTAL
Intervention: Management of local intravascular coagulopathy (LIC) with low‐molecular‐weight heparin (LMWH) and other anticoagulants
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Various treatment options including compression, sclerotherapy, laser therapy, cryoablation, and surgery
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Targeted molecular therapies acting on the PI3Kinase/AKT/mTOR pathway
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Standardized risk stratification tools and quality of life (QOL) questionnaires
Number of subjects: 0
Study: 35749373

Group type: EXPERIMENTAL
Intervention: Warning Label (WL)
Number of subjects: 14880

Group type: COMPARATOR
Intervention: Guideline Daily Amount (GDA)
Number of subjects: 14880
Study: 34336630

Group type: EXPERIMENTAL
Intervention: 0.5 µ/kg dexmedetomidine with 20 mL bupivacaine 0.125% (Group L)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: 1 µ/kg dexmedetomidine with 20 mL bupivacaine 0.125% (Group M)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: 1.5 µ/kg dexmedetomidine with 20 mL bupivacaine 0.125% (Group H)
Number of subjects: 80
Study: 34039876

Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT) for 16 weeks followed by a 12-week maintenance phase with mobile health coaching.
Number of subjects: 100

Group type: COMPARATOR
Intervention: Continuous Moderate Exercise (CME) for 16 weeks followed by a 12-week maintenance phase with mobile health coaching.
Number of subjects: 100
Study: 34600297

Group type: EXPERIMENTAL
Intervention: Go trials (50% probability)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cued condition (80% Go probability)
Number of subjects: 0
Study: 34816311

Group type: EXPERIMENTAL
Intervention: Reverse‐TAP
Number of subjects: 52

Group type: COMPARATOR
Intervention: DK‐crush
Number of subjects: 52
Study: 33481401

Group type: EXPERIMENTAL
Intervention: Nitric oxide
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: fHb ratio
Number of subjects: 110
Study: 33420349

Group type: EXPERIMENTAL
Intervention: Genotype-guided pain management
Number of subjects: 260

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 260
Study: 33715871

Group type: EXPERIMENTAL
Intervention: Ulipristal acetate (UPA) 10 mg orally once a day for 12 weeks
Number of subjects: 161

Group type: COMPARATOR
Intervention: Leuprorelin acetate (LEU) 1.88 mg or 3.75 mg subcutaneously at weeks 0, 4, and 8
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Ulipristal acetate (UPA)
Number of subjects: 161

Group type: COMPARATOR
Intervention: Leuprorelin acetate (LEU)
Number of subjects: 161
Study: 35801957

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 330
Study: 32920492

Group type: EXPERIMENTAL
Intervention: Blonanserin (BNS)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Olanzapine (OLZ)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 61
Study: 33764158

Group type: EXPERIMENTAL
Intervention: IMACS Risk Score
Number of subjects: 15187

Group type: COMPARATOR
Intervention: Heartmate II Risk Score
Number of subjects: 15187
Study: 33186365

Group type: EXPERIMENTAL
Intervention: ACTION Respecting Choices ACP intervention
Number of subjects: 1117

Group type: COMPARATOR
Intervention: Care as usual (Control)
Number of subjects: 1117
Study: 35477635

Group type: EXPERIMENTAL
Intervention: REL-1017 25 mg (75 mg loading dose on day 1)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: REL-1017 50 mg (100 mg loading dose on day 1)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study: 34865562

Group type: EXPERIMENTAL
Intervention: Stress group (experienced stressors including smoke, fire, and explosions)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (no stressors)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Stress group
Number of subjects: 40
Study: 36438822

Group type: EXPERIMENTAL
Intervention: Kampo group receiving mixed extract granules of kakkonto (2.5 g) and shosaikotokakikyosekko (2.5 g) three times a day for 14 days in addition to conventional treatment
Number of subjects: 161

Group type: COMPARATOR
Intervention: Control group receiving conventional treatment for symptom relief such as antipyretics and antitussives
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Kampo group
Number of subjects: 161
Study: 35999689

Group type: EXPERIMENTAL
Intervention: Inspiring Virtual Enabled Resources following Vascular Events (iVERVE) - electronic messages aligned to personal goals, 4-week duration.
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control group - limited administrative messages.
Number of subjects: 54
Study: 33545619

Group type: EXPERIMENTAL
Intervention: Italian version of the Body Appreciation Scale-2 (BAS-2)
Number of subjects: 601